Skip to main content
Equibles

Omead Ostadan

Equibles does not estimate personal net worth.

About Omead Ostadan

Earlier roles on record: COO and Board Member at Seer, Inc. (SEER) until September 30, 2022. Seer, Inc. reported in an 8-K filed August 26, 2022 that Omead Ostadan resigned as Board of Directors, effective September 30, 2022. The proxy statement of Seer, Inc. reports total compensation of $3,340,306 for Omead Ostadan in fiscal 2022, including a base salary of $105,936. Disclosed compensation is on record for 3 fiscal years. Omead Ostadan has spoken on 6 earnings calls across 1 company, most recently for Seer, Inc. on August 9, 2022. The companies whose calls Omead Ostadan spoke on are classified in the Healthcare sector.

“On August 25, 2022, Omead Ostadan resigned from his position as President of Seer, Inc. (the "Company") and from its Board of Directors (the "Board") for personal reasons, each effective as of September 30, 2022.”
Seer, Inc. Form 8-K, filed August 26, 2022 · Read the filing

Omead Ostadan on recent calls

“We don't anticipate that PAS 2.0 will have a direct impact on our revenue for the rest of this year, especially since it is currently part of the overall Proteograph Product Suite offering.”
COO, Seer, Inc. Q2 FY2022 Earnings Call ·
“So far, yes, the sales are more heavily weighted toward commercial versus academic. As we had mentioned to you previously, we expect that to continue for some period of time because commercial entities typically go through a different set of funding cycles and are much more able to make decisions on a short-term basis.”
COO, Seer, Inc. Q1 FY2022 Earnings Call ·
“I'm excited by our strong commercial progress as we execute against our objectives for the year, and I believe that our measured approach to commercialization is paving the way for broad release customers to seamlessly adopt the Proteograph suite and scale their studies.”
COO, Seer, Inc. Q3 FY2021 Earnings Call ·
“I’m excited by our strong commercial progress as we execute against our objectives for the year. We have an expanding installed base of customers across discovery research, translational research, clinical development, and biomarker discovery, to name a few.”
COO, Seer, Inc. Q2 FY2021 Earnings Call ·
“There is increasing enthusiasm and evidence that we are on the right path and that our current and future offerings have the potential to play a significant role in advancing our understanding of biology.”
COO, Seer, Inc. Q1 FY2021 Earnings Call ·

Affiliation history

Company network

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2022 Seer, Inc. (SEER) $105,936 $3,340,306
2021 Seer, Inc. (SEER) $393,343 $4,598,363
2020 Seer, Inc. (SEER) $215,577 $6,674,802

Recent activity